Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
David P. Conrad(Ottawa Hospital), Harold Atkins(University of Ottawa), Jovian Tsang(Ottawa Hospital), John C. Bell(Ottawa Hospital), Chantal G. Lemay(University of Ottawa), Meaghan Maclean(University of Ottawa), Fabrice Le Bœuf(Ottawa Hospital), Theresa Falls(Ottawa Hospital), Kelley A. Parato, Jean‐Simon Diallo(University of Ottawa)
Cited by 35
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
|The Lancet Oncology|2008|522
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [ <sup>18</sup> F]Fluorodeoxyglucose and [ <sup>11</sup> C]Deoxyglucose
|Journal of Cerebral Blood Flow & Metabolism|1985|419